Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Year: 2024
Type: other
Abstract: Treatment-related adverse events in the MIBC cohort
Authors: Matthew T. Campbell, Amishi Y. Shah, Pavlos Msaouel, Nizar M. Tannir, Arlene O. Siefker-Radtke, Ashish M. Kamat, Neema Navai, Colin P.N. Dinney, Priya Rao, Charles C. Guo, Rahul A. Sheth, Aradhana M. Venkatesan, Rebecca S. Tidwell, Shalini S. Yadav, Aidi Gu, Hong Chen, Marc Macaluso, Fei Duan, Sreyashi Basu, Sonali Jindal, Padmanee Sharma
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402575286